

Washington State Health Care Authority Prescription Drug Program

626 8th Ave SE, Olympia, WA 98501

https://www.hca.wa.gov/about-hca/prescription-drug-program

6/27/2025

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective July 1, 2025:

Targeted Immune Modulator (TIM) reviewed 4/17/2024			
Ingredient Name	Label Name of Preferred Product	L&I	UMP
adalimumab-ADAZ	adalimumab-adaz auto-injector	Not	Yes
adalimumab-BWWD	Hadlima® syringe	participating	Yes
	Hadlima Pushtouch® auto-injector		Yes
apremilast	Otezla® tablet		Yes
etanercept	Enbrel Mini® auto-injector		Yes
	Enbrel Sureclick® auto-injector		Yes
guselkumab	Tremfya® solution		Yes
	Tremfya Pen® auto-injector		Yes
risankizumab-RZAA	Skyrizi [®] solution		Yes
	Skyrizi [®] syringe		Yes
secukinumab	Cosentyx® solution		Yes
	Cosentyx [®] syringe		Yes
	Cosentyx Sensoready Pen® auto injector		Yes
	pen		
tofacitinib citrate	Xeljanz [®] solution		Yes
	Xeljanz® tablet		Yes
	Xeljanz XR® tablet 24hr		Yes
ustekinumab	Stelara [®] solution		Yes
	Stelara [®] syringe		Yes
ustekinumab-AEKN	Selarsdi [®] syringe		Yes
ustekinumab-KFCE	Yesintek® syringe		Yes
ustekinumab-STBA	Steqeyma [®] syringe		Yes

The effect of this recommendation is to make Selarsdi, Steqeyma, and Yesintek preferred on the WA PDL, and to make Stelara non-preferred on the WA PDL.

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our website.

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (360) 725-1188 or by email at leta.evaskus@hca.wa.gov.

Sincerely, Dunal Sullem.

Donna Sullivan

Chief Pharmacy Officer
Clinical Quality and Care Transformation
Washington State Health Care Authority